Plus: Intermittent fasting; FDA approves CV indication for semaglutide, and more
Can't see the images? View as webpage.
Facebook
Twitter
LinkedIn
To ensure that you never miss an issue, please whitelist us.

Jan. 18, 2020 : Issue #1025

TOP STORIES - Diabetes News & Research

The Pluses and Minuses of Intermittent Fasting

How Childhood Cardiovascular Risks Affect Risk for Diabetes in Adulthood

Glycemic Control and Hypoglycemia in Continuous Glucose Monitoring
Letter from the Editor
Jan. 18, 2020

The phrase “If I had a dollar for every time....I would be a millionaire” is used often these days, and nowhere has it been more true than when talking about a cure for diabetes.

A quick search on our website shows over 100 articles written about a cure for diabetes.

This week our publisher, Steve Freed, takes a serious look at what has changed in the search for a cure, and why a 5 year timeline is now realistic.

We have moved our newsletters to a new server in order to provide you with a more robust experience. Please make sure to add news@mail.diabetesincontrol.com to your contacts/whitelist so you don’t miss a single issue.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief


Doctor's Option
lab test products include rapid tests and CLIA certified fingerstick lab tests.

Rapid tests offer immediate test results to provide doctors with point of care test results in as little as 90 seconds.

Fingerstick lab tests provide CLIA certified lab accurate results. Each fingerstick lab test collection kit comes with a prepaid postage return envelope and everything you need to obtain and collect your fingerstick blood sample in a 510K FDA approved device.

Fingerstick lab tests are great for people who want to monitor their blood sugar, cholesterol, lipids and other important bio-markers at home or on the go.

Visit Doctor's Option

Newsflash: FDA Approves Semaglutide for Reduction of CV Disease Risk


The FDA has approved the indication ― reduction of cardiovascular (CV) disease risk — for the injectable formulation of the GLP-1 agonist semaglutide (Ozempic, Novo Nordisk) in the treatment of type 2 diabetes. Semaglutide had a significant 26% lower risk for the primary composite outcome of first occurrence of CV death, nonfatal MI, or nonfatal stroke.  For the oral semaglutide (Rybelsus), they found that it had a 21% reduction in three-component MACE.

TOP STORIES - Diabetes News and Research

The Pluses and Minuses of Intermittent Fasting
Intermittent fasting is a form of eating pattern that involves time cycles of fasting and eating, and it may be the key to prolonging life. 
READ MORE
How Childhood Cardiovascular Risks Affect Risk for Diabetes in Adulthood
How do the things we experience when we are young affect our future health?
READ MORE
Glycemic Control and Hypoglycemia in Continuous Glucose Monitoring
Does continuous monitoring mean continuous improvement?
READ MORE

Did You Know: How Close Are We To A Type 1 Cure? Five Years?


GDF-15We have been promised a cure in five years for the last 40 years, until we realized that type 1 diabetes is a more complicated disease than anyone imagined. But now we are starting to see some exciting results suggesting that a cure in 5 years is more realistic.  Because type 1 diabetes has been incurable and has serious lifelong health consequences, prevention is a major research goal. These new possible therapies in research are getting us closer to a possible cure.

We now know that Inflammatory agents deplete growth differentiation factor 15 (GDF15) and kill susceptible beta cells to cause type 1 diabetes. Current research has shown us that adding back GDF15 protects beta cells in treated mice.

When the researchers measured levels of GDF15 in pancreas tissue from people with diabetes, they found the protein was depleted in their malfunctioning islet cells. But the key piece of evidence emerged when the scientists treated non-obese diabetic mice with GDF15, and it reduced the development of diabetes by 53%. “From the results, it was hypothesized that reduced GDF15 was not a good thing for islet survival, and indeed that was the case,” said Raghu Mirmira, a study principal investigator. “This work opens the way for us to consider these sorts of ‘islet protective factors’ as therapies to prevent or reverse type 1 diabetes. This approach differs substantially from current thinking that targets the immune system. While GDF15 may be one new therapy, we identified other proteins that may work in conjunction with GDF15, so this work represents a treasure-trove of information that can be mined for new therapies,” said Mirmira. The researchers are now working on the idea that low levels of GDF15 in islets may somehow be playing a proactive role in instigating the autoimmune attack that ultimately kills them. 

Mirmira, until recently, served as a professor of pediatric diabetes and director of the Center for Diabetes and Metabolic Diseases at Indiana University School of Medicine. He is now a professor of medicine in the Section of Endocrinology, Diabetes & Metabolism at the University of Chicago. Photo Credit: Courtesy of Pacific Northwest National Laboratory Cell Metabolism Jan 2020

Steve Freed, R.Ph, CDE, Publisher

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:


Usif Darwish, PharmD Candidate, Florida A&M University, College of Pharmacy & Pharmaceutical Sciences

Keri Hames, PharmD Candidate, Florida A&M University, College of Pharmacy & Pharmaceutical Sciences

Emma Kammerer, L|E|C|O|M Bradenton School of Pharmacy, PharmD Candidate

George McConnell, PharmD. Candidate, LECOM School of Pharmacy

Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy

Sandra Zaki, PharmD Candidate, Florida A&M University
 About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com
Facebook
Twitter
LinkedIn
©2019 HIPER, LLC. All rights reserved.

This email was sent by eHealthcare Solutions on behalf of:
Diabetes In Control
810 Bear Tavern Rd, Suite 102
Ewing, NJ, 08628, United States


DiabetesInControl.com | Contact Us
Subscription Center | Update Profile
Unsubscribe